Table 2 Estimated effect (EE) and effect size (ES) of change in longitudinal outcomes between program baseline (Q0) and active implementation (Q3)

Reach

 Number of patients with OUD

  EE (95% CI)

25.02 (−296.90, 346.94)

10.84 (−516.00, 537.68)

47.21 (−777.98, 872.40)

36.37 (−1314.97, 1387.72)

  ES (95% CI)

0.11 (−1.34, 1.56)

0.05 (−2.33, 2.42)

0.21 (−3.51, 3.93)

0.16 (−5.92, 6.25)

 Number patients prescribed MOUD

  EE (95% CI)

12.86 (5.45, 20.28)

9.73 (−2.42, 21.89)

17.76 (−1.25, 36.77)

8.02 (−23.14, 39.19)

  ES (95% CI)

0.19 (0.08, 0.31)

0.15 (−0.04, 0.33)

0.27 (−0.02, 0.55)

0.12 (−0.35, 0.59)

 Percent of patients prescribed MOUD^a

  EE (95% CI)

11.98 (7.76, 16.20)

22.60 (16.05, 29.15)

−4.63 (−7.87, −1.38)

−27.23 (−34.51, −19.94)

  ES (95% CI)

0.27 (0.18, 0.37)

0.51 (0.37, 0.66)

−0.11 (−0.18, −0.03)

−0.62 (−0.78, −0.45)

Adoption

 Number of prescribers

  EE (95% CI)

1.24 (0.90, 1.59)

2.18 (1.61, 2.75)

−0.23 (−1.12, 0.67)

−2.41 (−3.87, −0.95)

  ES (95% CI)

0.04 (0.03, 0.04)

0.06 (0.05, 0.08)

−0.01 (−0.03, 0.02)

−0.07 (−0.11, −0.03)

 Number of x-waivered prescribers

  EE (95% CI)

1.40 (1.23, 1.56)

1.55 (1.28, 1.82)

1.16 (0.74, 1.59)

−0.39 (−1.08, 0.31)

  ES (95% CI)

0.22 (0.20, 0.25)

0.25 (0.21, 0.30)

0.19 (0.12, 0.26)

−0.06 (−0.18, 0.05)

 Number of active x-waivered prescribers

  EE (95% CI)

1.32 (1.25, 1.40)

1.54 (1.42, 1.66)

0.99 (0.81, 1.18)

−0.54 (−0.85, −0.24)

  ES (95% CI)

0.34 (0.32, 0.36)

0.40 (0.37, 0.43)

0.26 (0.21, 0.31)

−0.14 (−0.22, −0.06)

 Percent of x-waivered prescribers

  EE (95% CI)

3.52 (3.43, 3.61)

2.41 (2.27, 2.56)

5.25 (5.02, 5.48)

2.84 (2.46, 3.21)

  ES (95% CI)

0.10 (0.10, 0.10)

0.07 (0.07, 0.07)

0.15 (0.14, 0.16)

0.08 (0.07, 0.09)

Implementation quality

 IMAT Implementation quality

  EE (95% CI)

0.53 (0.52, 0.55)

0.59 (0.56, 0.61)

0.45 (0.41, 0.49)

−0.14 (−0.20, −0.07)

  ES (95% CI)

0.68 (0.66, 0.70)

0.75 (0.72, 0.78)

0.58 (0.53, 0.63)

−0.18 (−0.26, −0.09)